(Image source from: indianexpress.com)
On Wednesday, while investors waited for the final analysis of its Covid-19 shots, Moderna rose upto 10% hitting a high record.
After a few days of 151 volunteers in the 30,000 person study, develop symptoms of the virus, then the final look at the data is expected.
This would be the final step before biotech company files for an emergency use authorization.
After Pfizer Inc was the first to file with U.S. regulators, Moderna is self-assured and considered to be the second company to do so.
On December 10, Pfizer and German partner BioNTech SE’s shot is expected to face a Food and Drug Administration panel.
In the preliminary assessment, Moderna’s shot was found to be about 94.5 per cent effective.
In the final analysis, Pfizer’s vaccinations looked similarly effective.
Goldman Sachs analyst, Salveen Richter, wrote in a note to clients that “Look for similar efficacy to be maintained”
Having said, Moderna’s stock price increased more than fivefold this year.
By Neha Makhija